Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:19 PM
Ignite Modification Date:
2025-12-24 @ 7:19 PM
NCT ID:
NCT00685503
Eligibility Criteria:
* INCLUSION CRITERIA:
* Participant must understand and sign the informed consent.
* Participant must be at least 18 years of age.
* Participant must have macular telangiectasia in both eyes.
* Participant must have neovascularization in the study eye.
* Participant must have vision loss of better than 20/400 in the study eye.
* Participant must have clear ocular media and adequate pupillary dilation to permit good quality stereoscopic fundus photography.
* All women of childbearing potential must have a negative urine pregnancy test at baseline, and be willing to undergo testing immediately prior to each injection and monthly for at least 2 months following the last dose of ranibizumab.
* Safety and toxicity of ranibizumab have not yet been investigated in children. Further, it is unlikely that younger participants will be able to comply with all examinations and intravitreal injections. Therefore, participants below the age of 18 will be excluded from participation in the study. This ocular condition is not commonly found in participants below the age of 18.
EXCLUSION CRITERIA:
* History (within past five years) of a myocardial infarction or cerebrovascular accident or evidence of severe cardiac disease (apparent in electrocardiogram abnormalities, clinical history of unstable angina, acute coronary syndrome, myocardial infarction, revascularization procedure within six months prior to baseline, atrial or ventricular tachyarrythmias requiring ongoing treatment).
* History of stroke within 12 months of study entry.
* History within the past 30 days of a chronic ocular or periocular infection (including any history of ocular herpes zoster).
* Current acute ocular or periocular infection.
* Any major surgical procedure within one month of study entry.
* Known serious allergies to fluorescein dye AND either indocyanine green dye iodine, or shellfish. Indocyanine green dye is contraindicated in patients with iodine and shellfish allergies.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00685503
Study Brief:
Protocol Section:
NCT00685503